Advance CRISPR/Cas9 Gene Editing Therapy for Duchenne
Gene editing technologies like CRISPR/Cas9 correct a majority of mutations causing Duchenne muscular dystrophy. Funding will allow Dr. Olson to advance the preclinical research which suggests this approach has the potential to treat up to 80 percent of children suffering from the disease. Dr. Eric Olson from UT Southwestern Medical Center is using CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy. CureDuchenne needs your help to support Dr. Olson’s research to accelerate subsequent exon programming.